Control of Steatorrhea in Participants With Cystic Fibrosis and Exocrine Pancreatic Insufficiency
Status:
Completed
Trial end date:
2012-05-01
Target enrollment:
Participant gender:
Summary
This study by Aptalis (formerly Axcan) assesses the efficacy and safety of Panzytrat® 25,000
compared to Kreon® 25,000 in the control of steatorrhea in participants with cystic fibrosis
(CF) and exocrine pancreatic insufficiency (EPI).